ABNOM
☆ AI Dermatology — Free Service
An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
relevance score : -100.0%
ReferencesDen Q‑switched Nd:YAG‑Laser ass bekannt fir effektiv Nevus vun Ota an ähnlech Konditiounen ze behandelen. Mir hunn eng Etude gemaach, fir ze kucken, wéi gutt en high‑fluence 1064 nm Q‑switched Nd:YAG‑Laser op mongolesche Flecken an ongewéinleche Gebidder wirkt, ouni datt d'Haut méi hell gëtt. Mir hunn 61 Patientinnen a Patienten mat dësen Flecken studéiert, am Ganzen 70 Läsionen ënnersicht. D'Halschent vun de Läsionen gouf mam Laser behandelt, déi aner goufen zum Verglach onbehandelt gelooss. Mir hunn d'Resultater evaluiert mat enger Skala an engem Apparat genannt Mexameter® fir Melaninniveauen ze moossen. D'Patientinnen a Patienten goufen am Duerchschnëtt 14 Méint an der Behandlungsgrupp an 18 Méint an der Observatiounsgrupp verfollegt. Um Enn vun der Studie hu mir bedeitend Differenzen an de Skala‑Scores a Melaninniveauen tëscht der Laser‑behandelte Grupp an der onbehandelte Grupp fonnt, wobei d'Laser‑behandelte Grupp besser Resultater weist. Den high‑fluence Q‑switched Nd:YAG‑Laser, ouni d'Haut liicht ze maachen, huet sech effektiv a sécher bewisen fir dës ongewéinlech mongolesch Flecken ze behandelen.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Mir hunn d'Effizienz a Sécherheet vun enger spezifescher Laserbehandlung fir ABNOM studéiert an gekuckt, wéi Faktore beaflossen, wéi gutt et funktionéiert. Mir hunn 110 Patienten analyséiert, déi ABNOM haten an tëscht zwee an néng Laserbehandlungen kruten. Mir hunn festgestallt, datt d'Behandlung besser funktionéiert, je länger se gedauert huet, awer net sou gutt bei eelere Patienten. Et huet och besser geschaf bei Patienten mat méi heller Haut (Typ III) a méi klenge betraffenen Beräicher (manner wéi 10 cm²). Melasma zesumme mam ABNOM huet d'Behandlung manner effektiv gemaach. D'Faarf oder d'Zuel vun de betraffenen Gebidder schéngen keen Ënnerscheed ze maachen. Ongeféier 10 % vun de Patienten hunn méi däischter Flecken no der Behandlung. Fréi Multiple Behandlungen hunn gutt Resultater geliwwert. Eeler Patienten mat méi däischer Haut a méi däischen Flecken sinn méi wahrscheinlech, no der Behandlung nach méi däischter Flecken ze kréien. Fir Patienten mat ABNOM a Melasma ass et besser, e Laser mat niddereger Energie ze benotzen, fir ze vermeiden, datt de Melasma verschlechtert gëtt.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Behandlung
Whitening‑Agenten hëllefen selten. Am Géigesaz zu Melasma kann ABNOM mat Laserbehandlung verbessert ginn an ouni Widderhuelung ewechgeholl ginn. Laserbehandlung kann 10 bis 20 Mol ausgefouert ginn fir ABNOM ze behandelen.
#QS1064 laser